- KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and after Surgery UroToday
Category: 6. Business
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and after Surgery – UroToday
-
Tiragolumab Plus Atezolizumab Fails to Improve Outcomes as Consolidation in NSCLC | Targeted Oncology
Consolidation therapy with tiragolumab plus atezolizumab (Tecentriq) failed to meet the primary end point of improving independent review facility (IRF)-assessed progression-free survival (PFS) vs standard durvalumab (Imfinzi) in patients with…
Continue Reading
-
Global AI Competition Could Create Trillion-Dollar Winners
Artificial intelligence (AI) represents a major opportunity for businesses across industries to develop products faster and cheaper than ever before. The race to gain a data-driven edge on the competition is fueling massive investment…
Continue Reading
-
T-DXd Superior to T-DM1 in Improving IDFS/DFS in Residual HER2+ Breast Cancer | Targeted Oncology
Interim data from the phase 3 DESTINY-Breast05 trial (NCT04622319) shared at the 2025 European Society for Medical Oncology (ESMO) Congress showed improved invasive disease–free survival (IDFS) with fam-trastuzumab deruxtecan-nxki (T-DXd;…
Continue Reading
-
Invikafusp Alfa Boasts High Disease Control Rate in Checkpoint Inhibitor–Resistant Solid Tumors
Invikafusp alfa led to tumor regression in target lesions in 52% of patients with tumor mutational burden–high (TMB-H) or microsatellite instability–high (MSI-H) solid tumors resistant to immune checkpoint blockade, according to data from…
Continue Reading
-
Pembrolizumab Plus Paclitaxel +/– Bevacizumab Yields Survival Advantages in Recurrent PROC
The combination of pembrolizumab (Keytruda) plus weekly paclitaxel with or without bevacizumab (Avastin) generated a statistically significant progression-free survival (PFS) benefit vs placebo plus paclitaxel with or without bevacizumab…
Continue Reading
-
Reliance Industries Ltd (WBO:RLI) Q2 2026 Earnings Call Highlights: Strong Growth Across …
This article first appeared on GuruFocus.
Release Date: October 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
Reliance Industries Ltd (WBO:RLI) reported strong…
Continue Reading
-
-
Rate of Second Primary Tumors Is Similar Between Adjuvant Cemiplimab and Placebo in High-Risk CSCC
Adjuvant treatment with cemiplimab-rwlc (Libtayo) was associated with a similar incidence of second primary tumors (SPTs) compared with placebo in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and…
Continue Reading
-
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
Treatment with tarlatamab-dlle (Imdelltra) improved overall survival (OS) vs chemotherapy among patients with small cell lung cancer (SCLC) regardless of chemotherapy-free intervals (CFIs) or prior receipt of anti–PD-(L)1 therapy, according to…
Continue Reading
-
ESMO 2025: Perioperative Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible: The Phase 3 KEYNOTE-905 Study – UroToday
- ESMO 2025: Perioperative Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible: The Phase 3 KEYNOTE-905 Study UroToday
- PADCEV™ Plus KEYTRUDA™, Given Before…
Continue Reading